The WIN Consortium is a global collaboration of leading healthcare
organizations that have joined together around the shared mission of
achieving the rapid translation of personalized cancer medicine
discoveries into standards for clinical care for patients around the
world.

“We are thrilled that these organizations are joining WIN,” said
Dr. John Mendelsohn, Chairman of the WIN Consortium. “They bring
immense capabilities and expertise that will be invaluable in building
our shared capacity to impact the lives of cancer patients around the
world through advancing personalized cancer medicine.”

Representing sixteen countries and four continents, WIN members now
include 39 leading organizations from the academic, industry, and the
non-profit sectors, who share information and collaboratively conduct
multi-institutional, global clinical trials and scientific projects that
aim to discover and validate significant advances in genomic and
biomarker-driven cancer medicine.

Prof. Carlos Caldas, Professor of Cancer Medicine and Senior Group
Leader at the Cancer Research UK Cambridge Institute said, 'The
Cambridge Cancer Centre and the University of Cambridge are committed to
applying our scientific and clinical expertise through innovative and
global partnerships to prevent and alleviate the suffering of patients
with cancer. The WIN Consortium represents a unique combination of
scientific and clinical skills from all elements of the healthcare
environment and we look forward to participating in furthering the
testing and implementation of individualized approaches to cancer
treatment”

Dr. Paul Sabbatini, Deputy Physician-in-Chief for Clinical Research at
Memorial Sloan Kettering Cancer Center, stated: “We are delighted for
Memorial Sloan Kettering Cancer Center to become a member of the WIN
group.We look forward to working closely with our colleagues and
believe that we have the greatest potential to accelerate the discovery
of effective treatments for patients by combining our intellectual and
scientific resources”.

Prof. Chang Sik Yu, Director of Asan Cancer Centre, noted that Asan
Cancer Centre shares WIN’s mission, vision, and values for improving the
lives of cancer patients. “Membership to WIN will provide us with the
opportunity to promoteground-breaking, global clinical trials
with other leading organizations to advance personalized cancer
medicine. With this opportunity, we hope to make an important
contribution to this worldwide effort to overcome cancer”.

Dr. Ian Walker, Cancer Research UK’s director of stratified medicine,
said: “Personalizing cancer treatments, by matching patients with the
therapies that will work best for them, could transform the lives of
people with the disease. Last year, Cancer Research UK spent over £40
million on research and infrastructure that will help deliver
personalized medicine for cancer patients.“We’re excited to
be part of the global initiative of translating our research into more
targeted treatments. By collaborating on innovative projects we can
accelerate progress and bring forward the day when all cancers are
cured.”

Founded in 2010 with leadership from the University of Texas MD Anderson
Cancer Center (USA) and the Institut Gustave Roussy (France), the WIN
Consortium is a non-profit, non-governmental organization headquartered
in Paris. WIN welcomes membership inquiries from organizations whose
capabilities and mission align with those of the Consortium.